Target Addition – consequences. As part of the Target Combination Addition Notice, Merck shall indicate whether the proposed Research Program activities relating to the Added Target Combination are to be directed towards the Discovery and Research of Monospecific Nanobodies directed against the Added Target Combination, and/or to be directed towards the Discovery and Research of Multispecific Nanobodies directed against the Added Target Combination. If the proposed Research Program activities are to be directed towards the Discovery and Research of Multispecific Nanobodies directed against the Added Target Combination, Merck shall also indicate the proposed Target Combinations to which said Multispecific Nanobodies are to be directed.
Appears in 5 contracts
Samples: Research Collaboration and Exclusive License Agreement (Ablynx NV), Research Collaboration and Exclusive License Agreement (Ablynx NV), Research Collaboration and Exclusive License Agreement (Ablynx NV)